OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/IDH1
Bile Duct Cancer (Cholangiocarcinoma)IDH1 Clinical Trials
IDH1 mutations occur in approximately 15–20% of intrahepatic cholangiocarcinoma and produce the oncometabolite 2-hydroxyglutarate (2-HG), driving epigenetic dysregulation. Ivosidenib is FDA-approved for previously treated IDH1-mutant advanced cholangiocarcinoma (ClarIDHy trial). Trials investigate ivosidenib combinations with PD-1 inhibitors and chemotherapy, and pan-IDH inhibitors covering both IDH1 and IDH2 mutations.
Top recruiting IDH1 Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and US site count. See all 5 trials matched to your profile →
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Servier Affaires Médicales
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
University Health Network, Toronto
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
Browse other molecular targets with active Bile Duct Cancer (Cholangiocarcinoma) trials.